Antiangiogenic effect of docetaxel and everolimus as individual and dual-drug-loaded micellar nanocarriers

Pharmaceutical Research

Volumn 31, Issue 3, 2014, Pages 660-669

  Mishra, Gyan P ^a   Doddapaneni, Bhuvana Shyam ^a   Nguyen, Duc ^a   Alani, Adam W G ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

antiangiogenesis; combination therapy; polymeric micelles

Indexed keywords

COPOLYMER; DOCETAXEL; EVEROLIMUS; MACROGOL; MACROGOL 2000; MACROGOL 4000; NANOCARRIER; POLYLACTIC ACID; POLYLACTIC ACID 2200; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED DRUG RELEASE; DRUG DIFFUSION; DRUG POTENTIATION; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; MAXIMUM TOLERATED DOSE; MICELLE; MICROTUBULE; MOLECULAR STABILITY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; DRUG CARRIERS; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LACTATES; MICE; MICELLES; POLYETHYLENE GLYCOLS; SIROLIMUS; TAXOIDS; TOXICITY TESTS, ACUTE;

EID: 84895476369     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1188-z     Document Type: Article

References (40)

1. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis. 2002;5(4):237-56.
2. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9(6):653-60.
3. Folkman J. Endogenous angiogenesis inhibitors. APMIS. 2004;112(7-8):496-507.
4. Li W, Hutnik M, Smith R, Li V. Understanding angiogenesis http://www.angio.org/ua.php (accessed April 16 2013).
5. Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1-18.
6. Bocci Gand Loupakis F. The possible role of chemotherapy in antiangiogenic drug resistance. Med Hypotheses. 2012;78(5):646-8.
7. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128-35.
8. Miller KD, Sweeney CJ, Sledge Jr GW. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol. 2001;19(4):1195-206.
9. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A. 2003;100(22):12917-22.
10. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 2002;62(23):6938-43.
11. Hayot C, Farinelle S, De Decker R, Decaestecker C, Darro F, Kiss R, et al. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int J Oncol. 2002;21(2):417-25.
12. Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs. 2003;14(1):13-9.
13. Vacca A, Ribatti D, Iurlaro M, Merchionne F, Nico B, Ria R, et al. Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res. 2002;11(1):103-18.
14. Murtagh J, Lu H, Schwartz EL. Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation. Cancer Res. 2006;66(16):8192-9.
15. Manegold PC, Paringer C, Kulka U, Krimmel K, Eichhorn ME, Wilkowski R, et al. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res. 2008;14(3):892-900.
16. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 2009;15(5):1612-22.
17. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5(8):671-88.
18. Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery. J Pharm Sci. 2003;92(7):1343-55.
19. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JF, Hennink WE. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res. 2010;27(12):2569-89.
20. Shin HC, Alani AW, Rao DA, Rockich NC, Kwon GS. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J Control Release. 2009;140(3):294-300.
21. Shin HC, Alani AW, Cho H, Bae Y, Kolesar JM, Kwon GS. A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. Mol Pharm. 2011;8(4):1257-65.
22. Hasenstein JR, Shin HC, Kasmerchak K, Buehler D, Kwon GS, Kozak KR. Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG. Mol Cancer Ther. 2012;11(10):2233-42.
23. Mazzaferro S, Bouchemal K, Gallard JF, Iorga BI, Cheron M, Gueutin C, et al. Bivalent sequential binding of docetaxel to methyl-beta-cyclodextrin. Int J Pharm. 2011;416(1):171-80.
24. Iwase Yand Maitani Y. Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma. Biol Pharm Bull. 2012;35(6):975-9.
25. Lee SW, Yun MH, Jeong SW, In CH, Kim JY, Seo MH, et al. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM using polymer-based delivery system. J Control Release. 2011;155(2):262-71.
26. Maciag T, Kadish J, Wilkins L, Stemerman MB, Weinstein R. Organizational behavior of human umbilical vein endothelial cells. J Cell Biol. 1982;94(3):511-20.
27. Vailhe B, Vittet D, Feige JJ. In vitro models of vasculogenesis and angiogenesis. Lab Investig. 2001;81(4):439-52.
28. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 2001;72(1-3):191-202.
29. Chou T-C, Martin N. CompuSyn, CompuSyn software for drug combinations and for general dose-effect analysis, and user's guide. Paramus: ComboSyn, Inc.; 2007.
30. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27-55.
31. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671-5.
32. Pasquier E, Andre N, Braguer D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr Cancer Drug Targets. 2007;7(6):566-81.
33. Pazdur R. FDA approval for doctaxel. http://www.cancer.gov/cancertopics/ druginfo/fda-docetaxel (accessed April 21 2013).
34. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011;10(11):868-80.
35. Pazdur R. FDA Approval for Everolimus. http://www.cancer.gov/ cancertopics/druginfo/fda-everolimus#Anchor-Breast (accessed April 21 2013).
36. Huh KM, Lee SC, Cho YW, Lee J, Jeong JH, Park K. Hydrotropic polymer micelle system for delivery of paclitaxel. J Control Release. 2005;101(1-3):59-68.
37. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol. 2002;282(5):C947-70.
38. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, Schwartz EL. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther. 2002;1(13):1191-200.
39. Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res. 2007;13(9):2768-76.
40. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer. 2003;104(1):121-9.